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Abstract
Background: The close connection between neuronal activity and glucose consumption accounts for the clinical
value of 18F-fluoro-2-deoxyglucose (FDG) imaging in neurodegenerative disorders. Nevertheless, brain metabolic
response to starvation (STS) might hamper the diagnostic accuracy of FDG PET/CT when the cognitive impairment
results in a severe food deprivation.
Methods: Thirty six-week-old BALB/c female mice were divided into two groups: “control” group (n = 15) were kept
under standard conditions and exposed to fasting for 6 h before the study; the remaining “STS” mice were submitted
to 48 h STS (absence of food and free access to water) before imaging. In each group, nine mice were submitted to
dynamic micro-PET imaging to estimate brain and skeletal muscle glucose consumption (C- and SM-MRGlu*) by Patlak
approach, while six mice were sacrificed for ex vivo determination of the lumped constant, defined as the ratio
between CMRGlu* and glucose consumption measured by glucose removal from the incubation medium (n = 3)
or biochemical analyses (n = 3), respectively.
Results: CMRGlu* was lower in starved than in control mice (46.1 ± 23.3 vs 119.5 ± 40.2 nmol ×min−1 × g−1, respectively,
p < 0.001). Ex vivo evaluation documented a remarkable stability of lumped constant as documented by the stability of
GLUT expression, G6Pase activity, and kinetic features of hexokinase-catalyzed phosphorylation. However, brain SUV in
STS mice was even (though not significantly) higher with respect to control mice. Conversely, a marked decrease in
both SM-MRGlu* and SM-SUV was documented in STS mice with respect to controls.
Conclusions: STS markedly decreases brain glucose consumption without altering measured FDG SUV in mouse
experimental models. This apparent paradox does not reflect any change in lumped constant. Rather, it might be
explained by the metabolic response of the whole body: the decrease in FDG sequestration by the skeletal muscle is as
profound as to prolong tracer persistence in the bloodstream and thus its availability for brain uptake.
Keywords: Brain metabolism, PET/CT imaging, FDG, Starvation, Neuroimaging
* Correspondence: cecilia.marini@unige.it
2Nuclear Medicine Unit, Polyclinic San Martino Hospital, Largo R. Benzi 10,
16132 Genoa, Italy
15CNR Institute of Molecular Bioimaging and Physiology (IBFM), Milan, Italy
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Buschiazzo et al. EJNMMI Research  (2018) 8:44 
https://doi.org/10.1186/s13550-018-0398-0
Background
Under physiological conditions, the adult brain exclusively
depends on glucose oxidation to fuel the high-energy
demand for uptake recycling of neurotransmitters and
maintenance of ion gradients [1–3]. Local glucose con-
sumption is thus selectively modulated by neuronal activa-
tion while being relatively independent of hormonal
whole body-derived signals. These principles represent
the physiological basis underlying the clinical value of
18F-fluoro-2-deoxyglucose (FDG) imaging in different
neurodegenerative disorders [4].
Nevertheless, although “brain metabolic independence”
has been consistently documented under physiological
conditions, a wide literature also reported a measurable
response of brain metabolism to severe starvation [5, 6].
This condition can be frequently encountered in patients
with Alzheimer’s disease in whom the cognitive impair-
ment can often result in prolonged reduction in food in-
take with consequent body weight loss.
From the clinical point of view, this impairment con-
tributes to disease progression, particularly in advanced
age, as indicated by large epidemiologic studies [7–9].
From the methodological point of view, the possible
consequences on diagnostic accuracy of FDG imaging
are less certain. In fact, the reduction in glucose avail-
ability, combined with the increase in circulating levels
of beta-hydroxybutyrate (BHB) and acetoacetate induced
by starvation, can switch brain metabolism from a pref-
erential (if not exclusive) glycolytic pattern to a prevalent
oxidation of ketone bodies [1, 2, 10, 11]. The consequent
reduction in CMRGlu might obviously decrease FDG re-
tention thus asking for dedicated procedures to optimize
image quality and counting statistics. On the other hand,
the metabolic shift might modify neuronal gene expres-
sion profile, promoting the appearance of GLUT carriers
and hexokinase isoforms with different affinities for glu-
cose and FDG. This condition might alter the ratio be-
tween glucose consumption (CMRGlu) and its index
provided by FDG uptake (CMRGlu*) thus modifying the
lumped constant value [12, 13]. Finally, the systemic
adaptation to food deprivation decreases glucose dis-
posal and FDG sequestration in the whole body, pro-
tracting tracer persistence in the bloodstream as to
preserve or even increase brain FDG uptake indexed by
SUV. The present study aimed to define whether and
how the interplay among these three factors induced by
starvation interferes with brain FDG uptake and thus
with the diagnostic accuracy of PET/CT imaging in neu-
rodegenerative diseases.
Methods
Animal models
Six-week-old BALB/c female mice (The Charles River
Laboratories, Italy) were housed in sterile enclosures
under specific pathogen-free conditions. The 30 mice
were divided into two groups: with 15 animals, the “con-
trol” group were kept under standard conditions and ex-
posed to fasting for 6 h before the study; the remaining
animals were submitted to 48 h of starvation (“STS,” ab-
sence of food and free access to water) before imaging.
In each group, nine mice were submitted to micro-PET
imaging while six mice were sacrificed for the ex vivo
studies and thus for measurement of FDG uptake (n = 3)
or biochemical analyses (n = 3), respectively.
Experimental micro-PET scanning protocol
In vivo imaging was performed according to our vali-
dated procedure [14]. Anesthesia was induced by intra-
peritoneal administration of ketamine (100 mg/kg) and
xylazine (10 mg/kg). Capillary glucose level and body
weight were measured, and mice were positioned on the
bed of a dedicated micro-PET system (Albira, Bruker
Inc., USA). A dose of 3–4 MBq of FDG was then
injected through a tail vein, soon after the start of a list
mode acquisition lasting 50 min.
Image processing
List data were divided according to the following framing
rate: 10 × 15 s, 5 × 30 s, 2 × 150 s, 6 × 300 s, 1 × 600 s, and
then reconstructed using a maximal likelihood expect-
ation maximization method (MLEM). Two nuclear doc-
tors unaware of mouse allocation drew a volume of
interest (VOI) in the left ventricular chamber to plot the
time-concentration curve in arterial blood throughout the
whole acquisition (input function). Whole body FDG
clearance (in ml ×min−1) was calculated using the conven-
tional stochastic approach as the ratio between injected
dose and integral of input function, fitting the last 20 min
with a mono-exponential function [15]. In vivo CMRGlu*
was estimated according to Gjedde-Patlak [16] graphical
analysis by using the routine of dedicated software
(PMOD, Zurich, Switzerland) with lumped constant value
set at 1. On these parametric maps, two VOIs were drawn
to estimate the average brain (CMRGlu*) and skeletal
muscle (SM-MRGlu*) in nMol ×min−1 × g−1. These same
VOIs were thus transferred on the last 600-s frame to esti-
mate FDG standardized uptake value (SUV). According to
the same procedure, at regional analysis, cortical and cere-
bellar CMRGlu* and SUV were estimated to calculate the
cortical/cerebellum ratio in the two studied subgroups of
animals.
Ex vivo experiments
For “ex vivo” evaluation, each brain was harvested soon
after sacrifice, stuck in the outer ring of a Petri dish with
octyl-cyanoacrylate (Dermabond, Ethicon, USA), and cov-
ered with 2 mL solution collected from an input vial con-
taining 3 mL of DMEM medium (12.5 mM glucose) with
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a known FDG concentration (1 MBq/mL). Time-activity
curve (TAC) of tracer uptake was thus plotted using the
Ligand Tracer White device (Ridgeview, Uppsala, Se) [17,
18]. Briefly, this instrument consists of a beta-emission de-
tector and a rotating platform harboring a standard Petri
dish. The rotation axis is inclined at 30° from the vertical,
so that the medium covers the dish nadir while the de-
tector points at its zenith. All experiments consisted of 45
periodic rotations lasting 1 min and divided into four in-
tervals: (a) brain kept for 25 s in the system nadir and thus
fully immersed in the incubation medium, (b) 5-s 180°
counter-clockwise rotation, (c) brain kept for 25 s under
the detector at the system zenith and, finally, and (d) 5-s
180° counter-clockwise rotation for cycle restart. At each
cycle, the detector measures background and target count-
ing rates (in counts per second, CPS) in phases a and c,
respectively. FDG brain TAC was thus obtained by sub-
tracting the background counting rate from the corre-
sponding target value [19].
At the end of the experiment, an aliquot of 0.5 mL
was sampled both from input vial and from Petri dish
(output) to measure glucose concentration (mM) and
total FDG activity (MBq). Brain TAC was thus normal-
ized by multiplying brain counting rate at each time t
(BCR(t)) for the following factor:
BFD tð Þ ¼ BCR tð Þ  1
BCR 45 minð Þ
 Ainput−Aoutput
 
Ainput
ð1Þ
where BFD(t) represents the fraction of the dose present
in the brain at each time t, BCR(45 min) represents the
brain counting rate in the last minute, Ainput and Aoutput
represent FDG activity in MBq at experiment start and
end, respectively.
The closed system nature of the Ligand tracer permit-
ted us to consider the input function (IF) as:
IF tð Þ ¼ 1−BFD tð Þ ð2Þ
BFD(t) and IF(t) were thus used according to Patlak
graphical analysis, assuming the volume invariance of
both incubation medium and the brain, during the ex-
periment, respectively. The regression line was defined
as:
BFDt
IFt
¼ a
R t
0 IFtdt
IFt
þ b ð3Þ
This curve was analyzed in order to verify the expected ac-
cumulation kinetics of FDG; the slope a was identified by
least squares’ definition of regression line and multiplied
for input glucose level to estimate CMRGlu*, with the star
denoting the FDG-based measurement of CMRGlu, ac-
cording to the original definition of Sokoloff et al. [20]. By
contrast, ex vivo CMRGlu (in nMol ×min−1) was mea-
sured by the equation:
CMRGlu ¼ Glucoseinput−Glucoseoutput
  nanoMol
mL
 
 2
45
ml
min
 
ð4Þ
where glucose represents glucose concentration (nM), 2
is the volume of used DMEM, and 45 is the experiment
duration.
Ex vivo imaging
Soon after the end of the ex vivo experiment, brains were
washed and frozen in isopentane chilled with dry ice for
sectioning with a cryomicrotome in slices 100 μM thick.
At least three sections per brain were placed on a micro-
scope slide and exposed to an imaging plate (Cyclone, Per-
kinElmer, USA) that provides an image resolution of
100 μm. Exposure time was optimized to 5 min. There-
after, brain sections were stained with hematoxylin/eosin
and photographed by inverted optical microscope. No
measurement of radioactivity content was attempted,
while autoradiography images were co-registered with the
histologic staining using ImageJ software.
Brain homogenate analysis
For biochemical analyses, brains were homogenized in
phosphate-buffer saline (PBS) solution with a Potter-
Elvehjem homogenizer. Proteins concentration was
performed by Bradford analysis [21]. The samples
were sonicated for 10 s in ice.
Western blot experiments were performed accordingly
to the standard procedure using 50 μg proteins for each
sample. Enzymatic assays were performed spectrophoto-
metrically in a double-beam spectrophotometer (UNI-
CAM UV2, Analytical S.n.c., Italy) using 100 μg of
protein for each sample.
Activities of hexokinase (HK), phosphofructokinase (PFK),
glucose-6-phosphate dehydrogenase (G6PD), G6Pase, and
Complex I (NADH-ubiquinone oxidoreductase) were
assayed according to the methods in our previously
validated procedure [14]. β-Hydroxy-butyrate-dehydrogenase
(BHBDH) activity was evaluated following reduction of
NAD+ at 340 nm using a solution of 200 mM Tris-HClpH
8, 2 mM NAD+, and 30 mM β-hydroxybutyrate. Glutha-
tione reductase activity was evaluated spectrophotometric-
ally, at 405 nm, using Glutathione Reductase Assay Kit
(Abcam: ab83461) following the manufacturer’s instruc-
tions. Real-time PCR evaluation was performed according
to the standard procedures of our lab [22].
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Value Km and Vmax for HK
Hexokinases (HK) Michaelis-Menten kinetics was evalu-
ated for in the presence of glucose and 2-deoxyglucose
(2DG; Sigma-Aldrich, Saint Louis, MO, USA). The kin-
etic characterization of HK was determined at pH 7.4
and 25 °C, by coupling hexose phosphorylation to the
reduction of NADP, recording the change in absorbance
at 340 nm. The studied initial concentrations were 0.05,
0.1, 1, 5, and 200 mM for glucose and 0.3, 5, 50, 100, and
200 mM for 2DG. To avoid the substrate selectivity,
G6PD was substituted with hexose-6P-dehydrogenase
(H6PD), as an enzyme able to process both hexoses. Vmax
(the maximum rate achieved by the system) and Km (the
Michaelis-Menten constant indicating the substrate con-
centration at which the reaction rate is Vmax/2) were de-
termined by Lineweaver-Burk double reciprocal plots.
Statistical analysis
Data are presented as mean ± standard deviation (SD).
For comparison between different groups, the null hy-
pothesis was tested by Student’s t test for paired or un-
paired data, as appropriate. Significance was considered
for p values p < 0.05. Statistical analyses were performed
using SPSS software 15.0 (Chicago, IL, USA).
Results
Micro-PET analysis of in vivo brain response to starvation
STS caused a significant reduction in body weight (12.7
± 0.3 vs 16.9 ± 0.9 g, in starved mice and controls,
respectively, p < 0.001) while its effect on serum glu-
cose level was less pronounced (3.78 ± 1.65 vs 4.78 ±
1.62 mmol/L, respectively, p = 0.15). Blood clearance
of FDG was significantly lower in starved mice with
respect to control ones (0.03 ± 0.01 vs 0.05 ± 0.01 mL ×
min−1, p < 0.01).
Compartmental analysis of dynamic micro-PET scans
documented a significant response of brain metabolism
to STS. In fact, both average slope of Patlak regression
line (0.013 ± 0.007 vs 0.027 ± 0.010 min−1, respectively,
p < 0.001) and CMRGlu* (46.1 ± 23.3 vs 119.5 ±
40.2 nmol × min−1 × g−1, respectively, p < 0.001) were
lower in starved than in control mice (Fig. 1). By con-
trast, the STS-related drop in whole body glucose dis-
posal, and the consequent prolongation of tracer
availability in the bloodstream, preserved the FDG up-
take in the brain, whose average SUV was even (though
not significantly) higher in STS than in control mice
(2.59 ± 0.36 vs 2.00 ± 0.66, respectively, p = 0.14, Fig. 1).
At regional analysis, CMRGlu* and SUV cortical/cere-
bellum ratio remained remarkably stable in both STS
and control mice.
This metabolic response was largely different in
skeletal muscles (SM) as confirmed by the marked
decrease in both hind limbs’ SM-MRGlu* (0.2 ± 0.15
vs 1.02 ± 0.4 nmol × g−1 × min−1 respectively, p < 0.01)
and average SUV (0.22 ± 0.1 vs 0.54 ± 0.3, respectively,
p < 0.01) in starved mice with respect to controls
(Fig. 2).
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Fig. 1 In vivo effect of STS on brain metabolism. In the upper part, on the left, brain parametric maps of representative control (CTR) and 48-h
starved (STS) mice are shown; representative images of basal metabolic activity of the whole brain expressed in average standardized uptake
value (SUV) are shown on the right. In the bottom, graphs of whole cerebral metabolic rate of glucose (CMRGlu*; nmol ×min−1 × g−1) and SUV
are displayed, respectively. Results indicate mean ± SD of nine mice per group; green bars represent control value, and blue bars represent STS value
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Ex vivo evaluation of CMRGlu and CMRGlu*
Autoradiography and its co-registration with hematoxylin/
eosin staining documented the expected selectivity of
tracer uptake in the gray matter, confirming the viability
of all six studied brains during the 45-min incubation
(Fig. 3a).
The ex vivo evaluation confirmed the STS effect on
brain metabolism documented in vivo. Despite the iden-
tical extracellular environments, previous 48-h food
deprivation markedly reduced all indexes of brain hexose
intake. In fact, fractional drop of glucose concentration
in the incubation medium was markedly lower in starved
than in control mice (0.05 ± 0.02 vs 0.11 ± 0.04%, re-
spectively, p < 0.05, Fig. 3b). A similar observation also
applied to the fractional loss of FDG (Fig. 3c) from the
incubation medium that was almost halved in brains
explanted from starved mice (0.037 ± 0.015%) with re-
spect to control ones (0.075 ± 0.02%; p < 0.01).
Obviously, this same response was documented by the
estimation of metabolic rates. In fact, CMRGlu was 61.1
± 16.1 nmol ×min−1 in control preparations and de-
creased to 28.27 ± 12.7 nmol × min−1 in STS ones (p <
0.01). This response closely agreed with the correspond-
ing CMRGlu*. In all brains, FDG time-activity curves
showed a linear increase during the whole experiment
(Fig. 3d) and thus confirmed the expected accumulation
kinetics of FDG. Similarly, Patlak regression plot showed
a good correlation with r values always ≥ 0.97. Again,
previous STS decreased CRMGlu* from 38.3 ± 11 to
17.8 ± 7.2 nmol ×min−1 (p < 0.05, Fig. 3d).
As a consequence, lumped constant value was not af-
fected by nutritional status. In fact, the ratio between
fractional removals of FDG and glucose from the
medium was superimposable in control and STS brains
as well as the ratio CMRGlu*/CMRGlu (Fig. 3e).
Starvation effect on determinants of glucose and FDG
entrapment
The marked reduction in glucose consumption and FDG
uptake induced by STS was not explained by changes in
the membrane hexose carriers. In fact, protein levels
(Fig. 4a) of the different GLUTs (GLUT 1–2–3–4) were
remarkably stable regardless of nutritional status.
A similar response was documented for HK isoforms.
Coherently with the literature [23], HK gene expression
profiling of brain homogenates documented high levels
of mRNA encoding for HK isoform I, with only trace
signals for isoforms HKII, HKIII, and HKIV. Nutritional
status did not significantly affect neither HK expression
profile (Fig. 4b) nor kinetic features of hexose phosphor-
ylation. In fact, estimated Vmax (Fig. 4c) and Km (Fig. 4d)
of HK-related catalysis were only trivially affected by
STS for both glucose and 2DG confirming the theoret-
ical basis for the observed lumped constant invariance.
S
M
-
ul
G
R
M
(
lo
monan
*m
i-1
*/
g-
1 )
S
M
-A
V
E
R
A
G
E
 S
U
V
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
CTR CTRSTS STS
STS SM-MRGluCTR SM-MRGlu CTR SM-SUV STS SM-SUV
0
24
0
10
p<0.01 p<0.01
Fig. 2 In vivo effect of STS on skeletal muscle metabolism. In the upper part, on the left, skeletal muscle parametric maps of representative
control (CTR) and 48-h starved (STS) mice are shown; representative images of basal metabolic activity of hind limbs skeletal muscle expressed in
average standardized uptake value (SUV) are shown on the right. In the bottom, graphs of hind limbs skeletal muscle metabolic rate of glucose
(SM-MRGlu*; nmol ×min−1 × g−1) and SUV are displayed, respectively. Results indicate mean ± SD of nine mice per group; green bars represent
control value, and blue bars represent STS value
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Although the expression of G6Pase was very low in
controls, Western blot analysis demonstrated a slight
and not significant reduction of protein amount in
starved brains (Fig. 4e). On the other hand, the activity
of G6Pase were found to be extremely low in brain ho-
mogenates under normal conditions and remained un-
changed regardless nutritional status (Fig. 4f ).
On the contrary, STS significantly reduced the catalytic
activity of PFK, the rate-limiting enzyme of glycolysis (3.7
± 0.6 × 10−2 vs 5.6 ± 0.1 × 10−2 mU/mg of proteins in STS
and control brains respectively, p < 0.01, Fig. 5a). In agree-
ment with this response, lactate release slightly decreased
(though not significantly) from 28 ± 9 in controls to 19 ±
6 nmol × min−1 in STS mice (p = 0.20). The evident re-
duction in glycolytic flux was not counterbalanced by
any response of PPP since its regulator G6PD showed
constant mRNA levels (0.35 ± 0.01 vs 0.30 ± 0.02 mean
normalized expression in control and STS brains, re-
spectively, p = ns), protein abundance (Fig. 5b), and ac-
tivity (Fig. 5c).
a
b c
d e
Fig. 3 Ex vivo evaluation of CMRGlu and CMRGlu*. a The autoradiography (first image), its co-registration with hematoxylin/eosin staining
(second picture) and the merging of the two results (third image). b The FDG time-activity curves expressed in percentage of dose. c The Patlak
regression plot. In each graph, control (CTR) mice are represented in green and starved (STS) mice in blue. d The CMRGlu (left) and CMRGlu*
(right) values expressed in nmol ×min−1 × g−1. e The lumped constant value obtained as CMRGlu*/CMRGlu
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Fig. 4 (See legend on next page.)
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As expected, the reduced hexose avidity induced by STS
was paralleled by a metabolic shift from a prevalent glyco-
lytic pattern to a preferential oxidation of ketone bodies
[24]. This concept was confirmed by the evaluation of
BHBDH activity that markedly increased in STS brain ly-
sates with respect to control ones (6.41 ± 0.96 vs 0.64 ±
0.09 mU/mg of proteins, respectively, p < 0.01, Fig. 5d).
Similarly, it was corroborated by the response of respira-
tory Complex I, whose activity significantly increased in
STS brain with respect to controls (0.92 ± 0.06 vs 0.59 ±
0.04 U/mg of proteins, respectively, p < 0.01; Fig. 5e). Fi-
nally, and in line with the respiratory burst intrinsically as-
sociated with ketone bodies catabolism, glutathione
reductase showed a significant increase after STS (Fig. 5f).
Discussion
The present study documents that starvation markedly
decreases brain glucose consumption without altering
(See figure on previous page.)
Fig. 4 STS effect on determinants of glucose and FDG entrapment. a The western blot analysis against GLUT1, GLUT2, GLUT3, and GLUT4 performed
in brain homogenate of control (CTR, green bars) and of starved mice (STS, blue bars). Protein levels of the different GLUT isoforms were remarkably
stable regardless of nutritional status. Data were expressed in percentage change over control ± SD of at least three experiments. The values have
been normalized on β-actin. b The HK gene expression profiling of brain homogenates in CTR (left) and STS mice (right) was obtained by real-time
PCR. The four different isoforms have been analyzed: HK I (blue bar), HK II (red bar), HK III (green bar), and HK IV (purple bar). Results are expressed in
mean normalized expression ± SD. Nutritional status did not affect this expression profile. c The HK activity of brain homogenate in CTR mice (green
bar) and in STS mice (blue bar) in the presence of glucose (left) and 2DG (right). Data are expressed in μmol ×min−1 ± SD of at least three experiments.
d HK Km expressed determined by Lineweaver-Burk double reciprocal plots. Data are expressed in mM± SD of at least three experiments. e, f the
western blot analysis against G6Pase and the G6Pase activities, respectively. In both graphs, CTR group is represented in blue and the STS mice in
green. Western blot results are expressed in percentage change over control ± SD of at least three experiments. Values have been normalized on
β-actin. The G6Pase activity was assayed in the presence of glucose-6P (left) and 2DG-6P (right), and the values are expressed in U ×mg of proteins−1 ±
SD of at least three experiments
a b c
d e f
Fig. 5 Metabolic machinery of starved brain. In each panel, green bars represent the brain homogenate of control (CTR) mice and the blue bars
represent the brain homogenate of starved (STS) mice. a The PFK activity expressed in mU ×mg of proteins−1 ± SD of at least three experiments.
The catalytic activity was reduced in STS brain homogenate with respect to CTR
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measured FDG SUV in mouse experimental models.
This apparent paradox does not reflect any change in
lumped constant since the ratio between tracer uptake
and glucose intake remains remarkably constant regard-
less of nutritional condition. Rather, it is explained by
the metabolic response of the whole body: the decrease
in FDG sequestration by the skeletal muscle is as pro-
found as to prolong tracer persistence in the blood-
stream and thus its availability for brain uptake.
Biochemical considerations
In the present study, control CMRGlu* was comparable
to the data reported by Kreissl et al. in mice exposed to
a similar fasting duration [25]. However, this value was
almost halved after 48-h STS. In agreement with the evi-
dent decrease in PFK [26] activity, this response con-
firms previous studies showing a profound deceleration
in brain glycolytic rate after prolonged food deprivation
and weight loss both in humans [5, 6] and rodents [27].
A similar consideration applies to the almost fivefold in-
crease of BHBDH activity in starved brains. This obser-
vation agrees with the acknowledged brain metabolic
response to STS in which the preferential utilization of
ketone bodies [28] accelerates cell respiration as con-
firmed by the enhancement in mitochondrial Complex I
function. Similarly, the relatively low OXPHOS efficiency
[24] of ketolysis, and the consequent rise in reactive oxy-
gen species, nicely explains the increase in glutathione re-
ductase activity [29] as a basic cell response to oxidative
stress.
Accordingly, the observed halving of CMRGlu* in-
duced by STS is coherent with a marked reduction in
brain glycolytic flux compensated by an accelerated
ketolysis. Although blood levels of ketone bodies were
not tested in our models, this concept is largely con-
firmed by the ex vivo part of our study. Explanted STS
brains were immersed in a medium with high glucose
concentrations and without any other competing sub-
strate. Under this condition, the reduced avidity for glu-
cose and FDG persisted in all brains harvested from STS
mice suggesting a profound shift in the metabolic ma-
chinery of studied nervous tissues.
Methodological considerations.
Besides its biochemical relevance, the pilot ex vivo
evaluation provides a direct experimental and theoretical
evidence of lumped constant stability under severe food
deprivation. Previous attempts to approach this issue in
vivo obtained conflicting results: the compartmental
analysis applied by Redies and coworkers [6] reported an
STS-related reduction in lumped constant that was not
confirmed by Hasselbalch et al. [30] who compared
CMRGlu (measured by Fick method) with CMRGlu*
(measured by brain kinetics of FDG uptake).
Our ex vivo approach permitted us to couple
tracer-based estimation of CMRGlu* with the direct
measurement of CMRGlu. The ratio between these
two variables remained remarkably stable in brains
harvested from normally fed or starved mice. The sta-
bility of lumped constant was confirmed by the in-
variance of its theoretical determinants. According to
the original Sokoloff statement, the ratio between glu-
cose intake and 2DG uptake reflects the different af-
finities for the two hexoses of factors regulating
transmembrane transport, hexose phosphorylation and
de-phosphorylation: GLUT expression (lambda) was
not affected by STS and, similarly, G6Pase activity
(phi) on both glucose and 2DG was unchanged re-
gardless nutritional condition. Moreover, direct mea-
surements of Km and Vmax for both glucose and 2DG
documented an absent effect of STS on HK isoforms
affinity for the two hexoses.
Accordingly, “ex vivo” experiments indicate that the
observed response of CMRGlu* to STS did reflect a pro-
found reduction in brain glycolytic rate. The preserved
(or even slightly increased) brain FDG SUV observed in
starved mice was instead explained by the relatively
more profound impairment in glucose utilization by the
whole body of starved mice. This response has been
already reported in the literature as a possible conse-
quence of the increased blood concentration of ketone
bodies under starvation [31]. In agreement with this
study, the severe (almost fivefold) reduction in skeletal
muscle avidity for FDG profoundly altered tracer kinet-
ics virtually halving its blood clearance (Fig. 6a). The
decreased CMRGlu halved the tracer extraction frac-
tion in STS brain (Fig. 6b). As a consequence, FDG
brain retention increased more slowly in starved mice
with respect to control ones. However, the longer dur-
ation of tracer availability prolongs the uptake process
up to values higher with respect to control SUVs
(Fig. 6c).
Altogether, the present study indicates that STS ac-
tually impairs brain glycolytic flux as documented by
the similar decrease in both CMRGlu and CMRGlu*.
This response reflects an adaptation in the enzymatic
machinery of cells populating the central nervous sys-
tem and persists under exposure to high glucose con-
centration without the competition of any other
metabolite.
Conclusions
From the methodological point of view, the present
findings confirm the theoretical limitations of brain
SUV as a surrogate of CMRGlu* in estimating brain
glucose consumption. However, the clinical interpret-
ation of FDG imaging mostly relies on the identification
of relative metabolic inhomogeneities as markers of
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neurodegenerative disorders. The virtually absent re-
sponse of FDG SUV to STS thus further confirm the
adequacy of current procedures even in underfed pa-
tients provided that time gap between injection and im-
aging is carefully respected. Defining the regional
distribution of STS effect throughout the different cor-
tical areas was not possible with our experimental
model. The relevance of this limitation is indicated by
documented heterogeneity in metabolic response to
food deprivation in the different brain structures [32,
33]. Nevertheless, the severe brain metabolic impair-
ment induced by STS indicates a possible predictive
power of regional CMRGlu*. This potential might con-
figure dynamic PET studies to evaluate the link between
nutritional status and neurodegeneration.
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